🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)

RecruitingNAAges 18 Years - anyAllProf. Franciszek Lukaszczyk Memorial Oncology Cen…
NCT07668869 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma. Patients with recurrent glioblastoma have limited treatment options and poor prognosis. TTFields is a non-invasive antimitotic therapy that has demonstrated efficacy in recurrent glioblastoma. Stereotactic radiosurgery is commonly used in selected patients with recurrent disease; however, treatment efficacy may be limited by the infiltrative nature of glioblastoma and challenges in accurate target delineation. The study hypothesizes that combining TTFields with FET-PET-guided stereotactic radiosurgery will improve one-year overall survival compared with TTFields alone. Participants will be randomized in a 1:1 ratio to receive either TTFields plus stereotactic radiosurgery or TTFie

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥18 years * Karnofsky Performance Status ≥70 * Histologically confirmed IDH-wildtype glioblastoma * First, second, or third recurrence * Radiological recurrence according to RANO 2.0 criteria * Prior radiotherapy and temozolomide treatment * At least 6 months since completion of previous radiotherapy * Contrast-enhancing recurrent lesion visible on MRI * Maximum recurrent lesion diameter ≤5 cm * Available molecular profile including IDH and MGMT status * Adequate hematologic, renal, and hepatic function * Written informed consent Exclusion Criteria: * Previous bevacizumab treatment * Planned chemotherapy or targeted therapy after study intervention * Previous stereotactic re-irradiation within the planned treatment field * More than three recurrences * Significant psychiatric disorders * Significant unrelated neurological disease * Implanted pacemaker, defibrillator, deep brain stimulator, or other incompatible electronic device * Pregnancy or breastfeeding * Active intracranial hemorrhage * Uncontrolled hypertension * Severe renal dysfunction * Participation in another interventional study likely to interfere with this study
💊

What it tests

  • Tumor Treating Fields (TTFields)
  • FET-PET-Guided Stereotactic Radiosurgery
📍

Where

1 site
Department of Neurooncology and Radiosurgery, Franciszek Lukaszczyk Oncology Center
Bydgoszcz, Poland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy